A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studiesCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-11-270OAAI
Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysisCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-11-172OAAI
Development of a Translational Exposure-Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug ProductsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-07-184OA
A randomized, cross-over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalenceCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82022-05-210OAAI
Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophyCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-01-0320OAAI
Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis ApproachCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52021-11-088PREAI
Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilateCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32021-02-1014OAAI
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic ModelingCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32020-12-1313OAAI
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal ImpairmentCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52020-12-106PREAI
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity ScoresCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32020-11-0317OAAI
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United StatesCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82020-02-139OAAI
PREDICTING THE COST-EFFECTIVENESS OF GENERIC VERSUS BRAND DABIGATRAN USING PHARMACOMETRIC ESTIMATES AMONG PATIENTS WITH ATRIAL FIBRILLATIONVALUE IN HEALTHIF62019-05-010OAAI
The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood-brain barrier (BBB) permeabilityMOLECULAR DIVERSITYIF3.82017-01-0348PREAI